Non-invasive T21 Testing Space Abuzz as Firms Jockey for Share of $1B Market, Battle over IP | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Taking aim at an opportunity that has been estimated at more than $1 billion in the US alone, several firms are using next-generation sequencing and other genomic technologies to break into the diagnostics market for fetal aneuploidy and chromosomal aberrations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.